晋江市2020~2022年免疫规划疫苗疑似预防接种异常反应监测分析  

Surveillance and Analysis Of Adverse Events Following Immunization of Immunization Program Vaccine in Jinjiang City From 2020 To 2022

作　　者：王瑜玥[1] 李秀春 WANG Yu-yue;LI Xiu-chun(Jinjiang Center for Disease Control and Prevention,Jinjiang 362200,China)

机构地区：[1]晋江市疾病预防控制中心,福建晋江362200

出　　处：《海峡药学》2023年第9期96-99,共4页Strait Pharmaceutical Journal

摘　　要：目的分析晋江市疑似预防接种异常反应(AEFI)的特征,评价监测质量及疫苗接种安全性。方法采用描述性方法对2020~2022年监测资料进行分析。结果晋江市2020~2022年共报告免疫规划疫苗AEFI 94例,报告发生率9.30/10万剂,异常反应发生率2.38/10万剂。全市19个镇街道均有报告,以池店镇、内坑镇最多;男女性别比为1.47∶1。年龄以1岁组最多,以第二季度报告最多,占42,55%;一般反应占73.4%,异常反应占23.53%,偶合症占1.06%。报告例数最多及报告发生率最高的均为百白破疫苗(占39.36%,报告发生率23.17/10万)。结论晋江市AEFI监测指标均达国家要求,异常反应报告敏感性较高,一般反应的监测力度还需加强,做好预防接种宣传教育工作,接种前知情告知、接种后留观等对预防接种工作正常运转至关重要。OBJECTIVE To analyze the characteristics of adverse events following immunization(AEFI)in Jinjiang City,and to evaluate the quality of surveillance and the safety of vaccination.METHODS Descriptive method was used to analyze the monitoring data from 2020 to 2022.RESULTS A total of 94 AEFI cases of EPI vaccines were reported in Jinjiang City from 2020 to 2022,with a reported incidence of 9.30 per 100000 doses and an abnormal reaction rate of 2.38 per 100000 doses.All 19 towns or streets in the city were reported,with Chidian Town and Neikeng Town the most;the sex ratio is 1.47∶1.The age group of 1 year old was the most,and the second quarter was the most,accounting for 42.55%.General reactions accounted for 73.4%,abnormal reactions accounted for 23.53%,and coupling accounted for 1.06%.The highest number of reported cases and the highest reported incidence were DPT vaccine(39.36%,23.17 per 100,000 doses).CONCLUSION The AEFI monitoring indicators in Jinjiang City all meet the national requirements,the sensitivity of abnormal reaction reports is high,and the monitoring of general reactions needs to be strengthened.It is very important to do a good job in vaccination publicity and education,inform before vaccination and observe after vaccination.

关 键 词：预防接种 异常反应 疾病监测 

分 类 号：R969.4[医药卫生—药理学]